Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease neuropathy, peripheral
Comorbidity C0026764|multiple myeloma
Sentences 12
PubMedID- 20932799 Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
PubMedID- 21654882 Its marked safety and comparable efficacy in multiple myeloma patients with pre-existing peripheral neuropathy makes it a drug that will integrate well with other active agents.
PubMedID- 22110934 peripheral neuropathy in patients with multiple myeloma occurs as both disease- and treatment-related complication in the relapsed and newly diagnosed setting.
PubMedID- 24505516 The condition may occur before initiating treatment.32 in a recent study by borrello et al., the incidence of peripheral neuropathy in patients with newly diagnosed multiple myeloma prior to the administration of any therapy was 15% which suggests that peripheral neuropathy is a symptom of the disease itself.33 furthermore, treating multiple myeloma might complicate the neuropathy; the latter is associated with agents used to treat the disease, such as bortezomib,7 thalidomide,34 and vincristine.35 recently, wilson and vallance-owen have suggested an interaction between myeloma-related factors and the patient's genetic background in the development of treatment-induced peripheral neuropathy with different molecular pathways being implicated in bortezomib-induced and vincristine-induced peripheral neuropathy.29 patients frequently complain of sensory symptoms, pain in a stocking-and-glove distribution, and proprioception changes that may affect normal daily living activities.36 studies looking into the association between bortezomib-induced neuropathy and diabetic neuropathy have yielded contradictory results.
PubMedID- 21749306 Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis.
PubMedID- 22297012 Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
PubMedID- 22363889 In a recent study by borrello et al., the incidence of peripheral neuropathy in patients with newly diagnosed multiple myeloma prior to the administration of any therapy was 15% which suggests that peripheral neuropathy is a symptom of the disease itself [33].
PubMedID- 20467223 [severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma].
PubMedID- 24867959 A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
PubMedID- 25154818 Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density.
PubMedID- 22193964 Management of treatment-emergent peripheral neuropathy in multiple myeloma.
PubMedID- 23372151 peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (rvd) therapy.

Page: 1